Phase 3b Study for Management of Ocular Side Effects in Subjects With EGFR-amplified Glioblastoma Receiving Depatuxizumab Mafodotin (ABT-414)
Phase of Trial: Phase III
Latest Information Update: 09 Jan 2019
At a glance
- Drugs Depatuxizumab mafodotin (Primary) ; Temozolomide
- Indications Glioblastoma; Gliosarcoma
- Focus Adverse reactions; Registrational
- Sponsors AbbVie
- 11 Dec 2018 Planned End Date changed from 21 Nov 2019 to 8 Mar 2020.
- 03 Aug 2018 Planned End Date changed from 24 Sep 2019 to 21 Nov 2019.
- 03 Aug 2018 Status changed from not yet recruiting to recruiting.